Literature DB >> 2607142

Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives.

E S Dimenäs1, I K Wiklund, C G Dahlöf, K G Lindvall, B K Olofsson, U H De Faire.   

Abstract

In this study, previously untreated subjects were randomly recruited from a blood pressure screening programme. After repeated measurement of blood pressure levels, the subjects were divided into three major groups: normotensives (n = 95), borderline hypertensives (n = 69) and hypertensives (n = 30). Three self-administered standardized questionnaires were used to measure different aspects of subjective well-being and symptoms: the Nottingham Health Profile (NHP), the Subjective Symptoms Assessment Profile (SSAP) and the Minor Symptoms Evaluation Profile (MSEP). The results indicate gradual differences between the three groups, the most pronounced symptoms being seen among the hypertensives. Statistically significant differences were found for cardiac and gastrointestinal symptoms as well as for emotional reactions, home life, social life, sex life and sleep. The differences in well-being and subjective symptoms noted between the groups are important in the evaluation of new antihypertensive agents. Self-administered questionnaires of the type used in this study could also be valuable in identifying symptoms and disturbances in subjective well-being related to the antihypertensive medication per se.

Entities:  

Mesh:

Year:  1989        PMID: 2607142     DOI: 10.1097/00004872-198911000-00006

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

Review 1.  A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research.

Authors:  R T Anderson; N K Aaronson; M Bullinger; W L McBee
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

2.  Aspects of quality of life on treatment with felodipine.

Authors:  E Dimenäs; M A Wallander; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Evaluation of three methods of symptom reporting in a clinical trial of felodipine.

Authors:  M A Wallander; E Dimenäs; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Quality of life is not negatively affected by diet and exercise intervention in healthy men with cardiovascular risk factors.

Authors:  M L Hellénius; C Dahlöf; H Aberg; I Krakau; U de Faire
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

Review 5.  Critical review of the international assessments of health-related quality of life.

Authors:  R T Anderson; N K Aaronson; D Wilkin
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 6.  Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers).

Authors:  Antonio Coca
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Gender, psychological well-being and somatic cardiovascular risk factors.

Authors:  G Rose; T Sivik; N Delimar
Journal:  Integr Physiol Behav Sci       Date:  1994 Oct-Dec

9.  Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. The Swedish Diltiazem-Metoprolol Multi-Centre Study Group.

Authors:  C Dahlöf; T Hedner; T Thulin; S Gustafsson; S O Olsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  General well-being during treatment with different ACE-inhibitors: two double-blind placebo-controlled cross-over studies in healthy volunteers.

Authors:  C Dahlöf; E Dimenäs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.